MCID: BLD048
MIFTS: 52

Bladder Transitional Cell Carcinoma malady

Cancer diseases, Nephrological diseases categories
Download this MalaCard

Summaries for Bladder Transitional Cell Carcinoma

About this section


Fully expand this MalaCard
Disease Ontology:8 A bladder carcinoma that has material basis in transitional cells located in the lining of the bladder.

MalaCards based summary: Bladder Transitional Cell Carcinoma, also known as transitional cell carcinoma of bladder, is related to transitional cell carcinoma and bladder carcinoma. An important gene associated with Bladder Transitional Cell Carcinoma is NOTCH1 (notch 1), and among its related pathways are Notch signaling pathway and Pre-NOTCH Expression and Processing. The compounds acnu and 10-hydroxycamptothecin have been mentioned in the context of this disorder. Affiliated tissues include the lining of the bladder, prostate and endothelial, and related mouse phenotypes are pigmentation and hearing/vestibular/ear.

Aliases & Classifications for Bladder Transitional Cell Carcinoma

About this section

Bladder Transitional Cell Carcinoma, Aliases & Descriptions:

Name: Bladder Transitional Cell Carcinoma 8 10
Transitional Cell Carcinoma of Bladder 8 62
Urothelial Bladder Carcinoma 8 62
 
Urinary Bladder Urothelial Carcinoma 8
Carcinoma Transitional Cell Bladder 44


Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer diseases
Anatomical: Nephrological diseases


External Ids:

Disease Ontology8 DOID:4006
NCIt39 C39851

Related Diseases for Bladder Transitional Cell Carcinoma

About this section

Diseases related to Bladder Transitional Cell Carcinoma via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 52)
idRelated DiseaseScoreTop Affiliating Genes
1transitional cell carcinoma32.2CGB, TP53, CDKN1A
2bladder carcinoma31.7CGB, TP53, CDKN1A
3papilloma30.6CDKN1A, TP53
4adenocarcinoma29.4TP53, CDKN1A, MMP10, NOTCH1, CGB, PRSS8
5invasive bladder transitional cell carcinoma10.7
6prostatitis10.4
7endotheliitis10.4
8pleomorphic carcinoma10.3
9large cell carcinoma10.3
10small cell carcinoma10.3
11li-fraumeni syndrome10.3CDKN1A, TP53
12bladder urothelial papillary carcinoma10.3
13sarcomatoid transitional cell carcinoma10.3
14amyloidosis10.3
15inverted papilloma10.3
16breast cancer, invasive ductal10.3TP53, CDKN1A
17thyroid cancer, anaplastic10.3CDKN1A, TP53
18cholera10.2
19cervicitis10.2
20herpes simplex10.2
21prostate adenocarcinoma10.2
22serotonin syndrome10.2CGB, NOTCH1
23retroperitoneal leiomyosarcoma10.2
24mammary paget's disease10.2
25leiomyosarcoma10.2
26hypoxia10.2
27laryngeal squamous cell carcinoma10.2TP53, CDKN1A
28oligodendroglioma10.2TP53, CDKN1A
29malignant glioma10.2CDKN1A, NOTCH1, TP53
30cervical cancer10.1TP53, NOTCH1, CDKN1A
31endometrial carcinoma10.1CDKN1A, FGF3, TP53
32colorectal cancer10.1FGF3, CDKN1A, TP53
33retinoblastoma10.0CDKN1A, FGF3, TP53
34cholangiocarcinoma10.0TP53, CGB
35colonic benign neoplasm10.0TP53, FGF3, CDKN1A
36oral cancer10.0CDKN1A, TP53
37pancreatic cancer10.0NOTCH1, TP53, CDKN1A
38brain cancer10.0TP53, NOTCH1, CGB, CDKN1A
39stomach cancer10.0FGF3, CDKN1A, TP53
40liver cancer10.0TP53, NOTCH1, FGF3, CDKN1A
41osteosarcoma10.0CGB, NOTCH1, CDKN1A, TP53
42squamous cell carcinoma of the head and neck9.9CDKN1A, MMP10, TP53
43prostate cancer9.9CGB, CDKN1A, PRSS8
44lung cancer9.9FGF3, TP53, CDKN1A, CGB
45leukemia9.9CGB, NOTCH1, CDKN1A, TP53
46burkitt's lymphoma9.8TP53, MMP10, CDKN1A, NOTCH1
47breast cancer9.8CDKN1A, CGB, NOTCH1, FGF3, TP53
48melanoma9.8TP53, NOTCH1, CDKN1A, CGB, FGF3
49non-small cell lung carcinoma9.7CDKN1A, MMP10, CGB, TP53
50adenoma9.7NR2F1, TP53, CDKN1A, FGF3, CGB

Graphical network of the top 20 diseases related to Bladder Transitional Cell Carcinoma:



Diseases related to bladder transitional cell carcinoma

Symptoms for Bladder Transitional Cell Carcinoma

About this section

Drugs & Therapeutics for Bladder Transitional Cell Carcinoma

About this section

Drug clinical trials:

Search ClinicalTrials for Bladder Transitional Cell Carcinoma

Search NIH Clinical Center for Bladder Transitional Cell Carcinoma

Genetic Tests for Bladder Transitional Cell Carcinoma

About this section

Anatomical Context for Bladder Transitional Cell Carcinoma

About this section

MalaCards organs/tissues related to Bladder Transitional Cell Carcinoma:

32
Prostate, Endothelial, Lymph node, Bone, Adipocyte, Kidney, Lung, Dentritic cells

FMA organs/tissues related to Bladder Transitional Cell Carcinoma:

14
The lining of the bladder

Animal Models for Bladder Transitional Cell Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Bladder Transitional Cell Carcinoma:

36 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.3NOTCH1, NR2F1, TP53
2MP:00053779.0NR2F1, NOTCH1, CDKN1A, FGF3
3MP:00053718.8TP53, PRSS8, CDKN1A, FGF3
4MP:00053918.6TP53, NR2F1, NOTCH1, CDKN1A
5MP:00053808.5TP53, PRSS8, NOTCH1, CDKN1A, FGF3
6MP:00053888.5CDKN1A, NOTCH1, MMP10, TP53
7MP:00053878.0CDKN1A, NOTCH1, PRSS8, MMP10, TP53
8MP:00030128.0FGF3, CDKN1A, NR2F1, PRSS8, HEPACAM, TP53
9MP:00036318.0TP53, PRSS8, NR2F1, NOTCH1, CDKN1A, FGF3
10MP:00107687.8TP53, PRSS8, NR2F1, NOTCH1, CDKN1A, FGF3
11MP:00028737.6TP53, MMP10, PRSS8, NR2F1, NOTCH1, FGF3

Publications for Bladder Transitional Cell Carcinoma

About this section

Articles related to Bladder Transitional Cell Carcinoma:

(show top 50)    (show all 169)
idTitleAuthorsYear
1
Overexpression of flotillin-1 is involved in proliferation and recurrence of bladder transitional cell carcinoma. (24890092)
2014
2
The expression sequence tag is an effective method for screening DNA segments that predict urinary bladder transitional cell carcinoma prognosis. (25336970)
2014
3
Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma. (25178936)
2014
4
Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma. (24567353)
2014
5
Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma. (23613251)
2013
6
Apoptosis of bladder transitional cell carcinoma T24 cells induced by adenovirus-mediated inducible nitric oxide synthase gene transfection. (24255584)
2013
7
Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery. (23511989)
2013
8
CXCR4 Expression in Bladder Transitional Cell Carcinoma and Its Relationship with Clinicopathological Features. (23988662)
2013
9
Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma. (24196429)
2013
10
Bladder transitional cell carcinoma and BK virus in a young kidney transplant recipient. (23231013)
2013
11
Redox- and expression-proteomic analysis of plasma biomarkers in bladder transitional cell carcinoma. (23090237)
2012
12
Recurrence patterns of bladder transitional cell carcinoma after radical cystectomy. (22893727)
2012
13
Metastatic bladder transitional cell carcinoma presenting as a vascularised cutaneous right arm lesion. (21779951)
2012
14
Genetic susceptibility of methylenetetrahydrofolate reductase (MTHFR) gene C677T, A1298C, and G1793A polymorphisms with risk for bladder transitional cell carcinoma in men. (21046286)
2011
15
Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma. (21672320)
2011
16
Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas. (20582552)
2010
17
Differences in shotgun protein expression profile between superficial bladder transitional cell carcinoma and normal urothelium. (18818109)
2009
18
Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin. (18538698)
2008
19
Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract. (18699961)
2008
20
Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma. (18410436)
2008
21
The prognostic significance of pathologic stage T0 on organ-confined bladder transitional cell carcinoma following radical cystectomy. (19077398)
2008
22
E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma. (18931551)
2008
23
Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. (17222615)
2007
24
Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma. (17302565)
2007
25
Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. (17011058)
2006
26
Differential gene expression profiling in aggressive bladder transitional cell carcinoma compared to the adjacent microscopically normal urothelium by microdissection-SMART cDNA PCR-SSH. (16357518)
2006
27
Survival and progression in high grade tumour subset of G2 and G3 pT1 bladder transitional cell carcinoma. (16784833)
2006
28
Evaluation of superficial bladder transitional-cell carcinoma by optical coherence tomography. (15989448)
2005
29
Heat shock protein 70 expression in relation to apoptosis in primary bladder transitional cell carcinoma. (16438908)
2005
30
Does human papillomavirus play a role in the development of bladder transitional cell carcinoma? A comparison of PCR and immunohistochemical analysis. (15677544)
2005
31
Bladder transitional cell carcinoma: correlation of contrast enhancement on computed tomography with histological grade and tumour angiogenesis. (15664576)
2005
32
Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1. (15492256)
2004
33
Evaluation of chromosome 8 and 11 aneuploidies in washings and biopsy materials of bladder transitional cell carcinoma. (12660029)
2003
34
Significance of activated matrix metalloproteinase 2 (MMP2) in progression of bladder transitional cell carcinoma]. (12948424)
2003
35
Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. (12651606)
2003
36
Monitoring gene expression profile changes in bladder transitional cell carcinoma using cDNA microarray. (12644218)
2002
37
High expression of human uroplakin Ia in urinary bladder transitional cell carcinoma. (12036448)
2002
38
Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. (11696726)
2001
39
Risk factors for the development of bladder transitional cell carcinoma following surgery for transitional cell carcinoma of the upper urinary tract. (11490207)
2001
40
The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma. (11490306)
2001
41
Correlative expression of glutathione S-transferase-pi and multidrug resistance associated protein in bladder transitional cell carcinoma. (12840920)
2000
42
Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens. (11108659)
2000
43
Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. (10499628)
1999
44
The loss of expression of transforming growth factor-beta receptors correlates with the histopathologic tumor grade in bladder transitional cell carcinoma patients. (10333714)
1999
45
p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage. (9187909)
1997
46
Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma. (1377428)
1992
47
Interferon-alpha can alter the lytic susceptibility of murine bladder transitional cell carcinoma (MBT-2) by their original poor specific cytotoxic tumor infiltrating lymphocytes. (1732635)
1992
48
Characterization of cell lines derived from a multiply aneuploid human bladder transitional-cell carcinoma, UCRU-BL-13. (2759734)
1989
49
Comparison of cell-associated and soluble galactosyltransferase isoenzymes from a human bladder transitional cell carcinoma line. (3105874)
1987
50
Galactosyl transferase activity in rat bladder transitional cell carcinoma lines and in exfoliated cells in urine during carcinogenesis and reversible hyperplasia. (6778604)
1980

Variations for Bladder Transitional Cell Carcinoma

About this section

Expression for genes affiliated with Bladder Transitional Cell Carcinoma

About this section
Expression patterns in normal tissues for genes affiliated with Bladder Transitional Cell Carcinoma

Search GEO for disease gene expression data for Bladder Transitional Cell Carcinoma.

Pathways for genes affiliated with Bladder Transitional Cell Carcinoma

About this section

Pathways related to Bladder Transitional Cell Carcinoma according to GeneCards/GeneDecks:

(show all 24)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
Notch signaling pathway37
9.8CDKN1A, NOTCH1
2
Show member pathways
9.8NOTCH1, TP53
39.8CDKN1A, TP53
4
Show member pathways
ATM Signaling Pathway37
9.8CDKN1A, TP53
5
Show member pathways
9.8CDKN1A, TP53
69.8CDKN1A, TP53
79.8CDKN1A, TP53
8
Show member pathways
9.8CDKN1A, TP53
99.8CDKN1A, TP53
109.8CDKN1A, TP53
11
Show member pathways
9.8CDKN1A, TP53
129.8CDKN1A, TP53
139.8TP53, CDKN1A
14
Show member pathways
Apoptosis and survival Apoptotic TNF family pathways60
9.8TP53, CDKN1A
159.8TP53, CDKN1A
169.8TP53, CDKN1A
179.8TP53, CDKN1A
189.6CGB, TP53
199.4CDKN1A, NOTCH1, TP53
209.3FGF3, CDKN1A, TP53
21
Show member pathways
Signaling Pathways in Glioblastoma37
9.3FGF3, CDKN1A, TP53
229.3TP53, CDKN1A, FGF3
239.3FGF3, CDKN1A, TP53
24
Show member pathways
8.2TP53, MMP10, NOTCH1, CDKN1A, FGF3

Compounds for genes affiliated with Bladder Transitional Cell Carcinoma

About this section

Compounds related to Bladder Transitional Cell Carcinoma according to GeneCards/GeneDecks:

(show all 39)
idCompoundScoreTop Affiliating Genes
1acnu4410.2CDKN1A, TP53
210-hydroxycamptothecin4410.2CDKN1A, TP53
37-hydroxystaurosporine44 1111.2TP53, CDKN1A
4tomudex4410.2TP53, CDKN1A
5hpvs4410.2CDKN1A, TP53
63,3-diindolylmethane4410.1CDKN1A, TP53
7olomoucine44 1111.1TP53, CDKN1A
8temozolomide44 1111.1CDKN1A, TP53
9hmba4410.1CDKN1A, TP53
10taxane4410.1CDKN1A, TP53
11noxa4410.1CDKN1A, TP53
12cd 4374410.1CDKN1A, TP53
13aphidicolin4410.1CDKN1A, TP53
14indole-3-carbinol4410.1CDKN1A, TP53
15sulindac44 1111.1CDKN1A, TP53
16depsipeptide4410.0CDKN1A, TP53
17methylmethanesulfonate4410.0CDKN1A, TP53
18suberoylanilide hydroxamic acid4410.0TP53, CDKN1A
19n-(4-hydroxyphenyl)retinamide4410.0CDKN1A, TP53
202-methoxyestradiol44 61 2412.0CDKN1A, TP53
21roscovitine4410.0TP53, CDKN1A
22benzo(a)pyrene449.9CDKN1A, TP53
23leptomycin b44 6110.9CDKN1A, TP53
24oxaliplatin44 50 1111.9TP53, CDKN1A
25flavopiridol44 1110.8CDKN1A, TP53
26ly294002449.7TP53, NOTCH1, CDKN1A
27doxorubicin44 50 1111.7TP53, NOTCH1, CDKN1A
28bortezomib44 50 1111.7TP53, CDKN1A
29etoposide44 50 61 1112.6TP53, CDKN1A, CGB
30bleomycin44 1110.6CGB, TP53
31pdtc449.5CDKN1A, TP53
32retinoic acid44 2410.2TP53, NR2F1, NOTCH1, CDKN1A
33cisplatin44 50 61 1112.2CGB, CDKN1A, TP53
34matrigel449.2MMP10, NOTCH1, CGB
35progesterone44 28 61 24 1113.1TP53, NR2F1, CDKN1A, CGB
36estrogen448.8TP53, NR2F1, NOTCH1, CDKN1A, CGB
37serine448.4TP53, MMP10, PRSS8, NOTCH1, CDKN1A
38oligonucleotide448.4TP53, MMP10, NR2F1, CDKN1A, FGF3
39vegf448.1FGF3, CGB, CDKN1A, NOTCH1, MMP10, TP53

GO Terms for genes affiliated with Bladder Transitional Cell Carcinoma

About this section

Cellular components related to Bladder Transitional Cell Carcinoma according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1nucleoplasmGO:0056548.9CDKN1A, NOTCH1, NR2F1, TP53
2extracellular regionGO:0055767.4FGF3, CGB, NOTCH1, PRSS8, MMP10

Biological processes related to Bladder Transitional Cell Carcinoma according to GeneCards/GeneDecks:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1mitotic cell cycle arrestGO:07185010.0CDKN1A, TP53
2cellular response to ionizing radiationGO:0714799.9TP53, CDKN1A
3positive regulation of reactive oxygen species metabolic processGO:20003799.9CDKN1A, TP53
4intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorGO:0427719.9CDKN1A, TP53
5cellular protein localizationGO:0346139.8TP53, HEPACAM
6Ras protein signal transductionGO:0072659.8CDKN1A, TP53
7intrinsic apoptotic signaling pathwayGO:0971939.7TP53, CDKN1A
8cell cycle arrestGO:0070509.5CDKN1A, HEPACAM, TP53
9DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestGO:0069779.5CDKN1A, TP53
10negative regulation of cell proliferationGO:0082859.4CDKN1A, NOTCH1, TP53

Products for genes affiliated with Bladder Transitional Cell Carcinoma

About this section
  • Antibodies
  • Proteins
  • Lysates

Sources for Bladder Transitional Cell Carcinoma

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
58SNOMED-CT via Orphanet
62UMLS
63UMLS via Orphanet